Scanning and combinatorial library services – Save 20% with code TRY-BXPLIB-20

Countering emerging Sars-CoV-2 variants

Recorded event – May 5, 2021

The global COVID-19 pandemic created an urgent need for protective interventions. With SARS-CoV-2 continuing to evolve, multiple approaches will likely be required to combat new viral variants as the scientific and pharmaceutical communities continue to develop anti-SARS-CoV-2 therapeutics and vaccines.

In this webinar, Dr. Jesse Erasmus from the University of Washington School of Medicine discusses his approach and how he mitigated key design and discovery hurdles to designing a framework for the scalable manufacturing and improved stability required for global vaccine distribution. Dr. Erasmus will further discuss his development of a two-vialed replicating RNA (repRNA) vaccine and Lipid InOrganic Nanoparticle (LION) platform that can be mixed immediately before injection.

Jesse Erasmus, PhD. is an Acting Assistant Professor at the University of Washington School of Medicine and the Director of Virology at HDT Bio. His research focuses on studying virus-derived mechanisms of gene expression for the development of new RNA vaccines and therapeutic technologies.

Contact us

The expertise of our scientists, engineers and supporting teams are at your service! Submit the form below and/or call us at 858.526.3080.

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

By clicking Submit, you agree that Telesis Bio may use this information to contact you about our programs, products, or services. You may opt out at any time.

Your personal data is handled according to our privacy policy. In addition, if you are located within a distributor territory, you may be contacted directly by them. We never sell your data to anyone.